Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight

New York, USA, April 08, 2026 (GLOBE NEWSWIRE) -- Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of...
April 08, 2026 08:30 ET | Source: Shared AI License Foundation

AI Pioneers Unite to Launch the Shared AI License Foundation to Advance Foundation Model Innovation

Summary: Leading AI companies announced the formation of the Shared AI License Foundation to promote the growth and development of foundation models.Participating companies grant non-exclusive...
April 07, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight

New York, USA, April 07, 2026 (GLOBE NEWSWIRE) -- Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight |...
April 06, 2026 17:59 ET | Source: Renovare Therapeutics, Inc.

Renovare Therapeutics, Inc. Announces Company Launch and Collaboration with CU Boulder Awardee of up to $33.5 Million in ARPA-H Funding to Advance Osteoarthritis Regenerative Therapies

Renovare Therapeutics announces company launch & collaboration with CU Boulder awardee of up to $33.5 million in ARPA-H funding for regenerative therapies
April 06, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight

New York, USA, April 06, 2026 (GLOBE NEWSWIRE) -- Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight The...
April 03, 2026 09:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Changes to Board of Directors

-- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage...
April 01, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight

New York, USA, April 01, 2026 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry |...
March 30, 2026 16:01 ET | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results

Sangamo Therapeutics reports recent business highlights and fourth quarter and full year 2025 financial results
March 30, 2026 05:25 ET | Source: Research and Markets

Non-Muscle Invasive Bladder Cancer (NMIBC) Market to Grow by $1 Billion During 2026-2030 - Johnson & Johnson, Janssen Research & Development, and Merck & Co. Lead the Competition

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Non-Muscle Invasive Bladder Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering. The non-muscle invasive bladder...
March 30, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply

The cobas MPX-E test provides four critical results (for HIV, HCV, HBV, and HEV) in a single test, increasing laboratory efficiency and decreasing healthcare costs.The new test delivers faster...